Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers. (Q36680096)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17161683%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

review article

1 reference

title

Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17161683%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17161683%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

author name string

Jean W Lee

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17161683%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

Julian Vasilescu

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17161683%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

language of work or name

1 reference

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17161683%20AND%20SRC:MED&resulttype=core&format=json

Advances in Cancer Research

23 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17161683%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

volume

96

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17161683%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

page(s)

269-298

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17161683%20AND%20SRC:MED&resulttype=core&format=json

Using literature and data to learn Bayesian networks as clinical models of ovarian tumors

23 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

Cancer biomarker validation: standards and process: roles for the National Institute of Standards and Technology (NIST).

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

Summary report of the Standards, Options and Recommendations for the use of serum tumour markers in breast cancer: 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

Potential Clinical Utility of Serum HER-2/neu Oncoprotein Concentrations in Patients with Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

Use of algorithms as determinants for individual patient decision making: national comprehensive cancer network versus artificial neural networks

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

The price of innovation: new estimates of drug development costs

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

Quantitative imaging of the T cell antitumor response by positron-emission tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

A census of human cancer genes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

Optimal replication and the importance of experimental design for gel-based quantitative proteomics.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

Proteomics: from gel based to gel free.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

Fit-for-purpose method development and validation for successful biomarker measurement.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

Measurement reproducibility in the early stages of biomarker development.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

Statistical and computational methods for comparative proteomic profiling using liquid chromatography-tandem mass spectrometry

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

Biomarkers of cancer risk and therapeutic benefit: new technologies, new opportunities, and some challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serum

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

Trends in development and approval times for new therapeutics in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

Biomarkers in cancer screening: a public health perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

Overview of biomarkers and surrogate endpoints in drug development

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

Large-scale analysis of the yeast proteome by multidimensional protein identification technology

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

Integromic analysis of the NCI-60 cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2806%2996010-2

7 January 2021

10.1016/S0065-230X(06)96010-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17161683%20AND%20SRC:MED&resulttype=core&format=json

release_kotz7mkjhzbaxhrp2rvhpwfaky

23 December 2019

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kotz7mkjhzbaxhrp2rvhpwfaky

24 November 2022

mapped directly with Wikidata item

1 reference